Presentations from 35th Annual International Prostate Cancer Update

SESSION 1: TechCon: Novel and New Technologies in Prostate Cancer

Update on Telesurgery and Novel Robotic Systems

David M. Albala, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 9, 2025, in Vail, Colorado.

Transurethral Ultrasound Guided Prostate Ablation (TULSA): Clinical Trials and Real-world Results

Christian P. Pavlovich, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 9, 2025, in Vail, Colorado.

Current Advances of Liquid Biopsies in Prostate Cancer

Edwin M. Posadas, MD, FACP, presented this lecture during the 35th Annual International Prostate Cancer Update on February 9, 2025, in Vail, Colorado.

MRI-Assisted Radiosurgery (MARS) Management of High Risk and Recurrent Prostate Cancer

Steven J. Frank, MD, FACR, FABS, FASTRO, presented this lecture during the 35th Annual International Prostate Cancer Update on February 9, 2025, in Vail, Colorado.

Panel Discussion: TechCon: Novel and New Technologies in Prostate Cancer

John W. Davis, MD, FACS, and Andrew W. Hahn, MD, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 9, 2025, in Vail, Colorado.

SESSION 2: Molecular Targeted Imaging (MTI)

Biochemical Recurrence after Radical Prostatectomy

Christian P. Pavlovich, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Optimizing Utilization of PSMA PET into a Urological Practice

David M. Albala, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Treating Oligometastatic Prostate Cancer in the PSMA PET Era

Andrew W. Hahn, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Reducing Imaging Denials: LUGPA Perspectives

Ronald P. Kaufman, Jr., MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Panel Discussion: Molecular Targeted Imaging (MTI)

A. Oliver Sartor, MD and Brian Helfand, MD, PhD, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

SESSION 3: Advances in Testing and Diagnosis

Update: Studies Combining Secondary Biomarkers and MRI

Leonard G. Gomella, MD, FACS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Biopsy Updates: Do We Have Clarity?

Ronald P. Kaufman, Jr., MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Secondary Biomarkers for Prostate Cancer Clinical Overview 2025

Christian P. Pavlovich, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Panel Discussion: Advances in Testing and Diagnosis

Leonard G. Gomella, MD, FACS, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

SESSION 4: Germline, Molecular Detection, and Screening

Identification and Management of High-Risk Screening Populations

Brian T. Helfand, MD, PhD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Prostate Cancer Management Decisions From Germline and Somatic Testing

Leonard G. Gomella, MD, FACS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Updates on Global Screening Trials Where Are We Headed Next

R. Jonathan Henderson, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Grade Group 1 at Biopsy—Do We Need to Know More?

John W. Davis, MD, FACS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Panel Discussion: Germline, Molecular Detection, and Screening

J. Ryan, MD, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

The Evolution of Genetic Testing in the Management of Prostate Cancer

Leonard G. Gomella, MD, FACS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Genomic Biomarker Roundtable

Leonard G. Gomella, MD, FACS, and Brian T. Helfand, MD, PhD, moderated this roundtable discussion during the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

SESSION 5: Approaches in Local Therapy for Prostate Cancer

The Undecided PCA Consult: Optimized Counseling, Treatment Choices, Avoiding Decision Regret

Jonathan D. Tward, MD, PhD, FASTRO, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer

Jason A. Efstathiou, MD, DPhil, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Lessons Learned from High Impact Randomized Trials

Mira Keyes MD, FRCPC, FABS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Panel Discussion: Approaches in Local Therapy for Prostate Cancer

Peter F. Orio III, DO, MS, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Brian J. Moran Distinguished Lecture: Brian Moran – An Unmatched Legacy of Permanent Prostate Brachytherapy

Brian J. Davis, MD, PhD, FABS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

SESSION 6: Focal Therapy

Focal Therapy Clinical Trials – Concepts and Challenges

Steven J. Frank, MD, FACR, FABS, FASTRO, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Focal Therapies for Prostate Cancer: Recurrent versus Persistent Disease Management

Brian T. Helfand, MD, PhD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Focal Brachytherapy in 2025

Peter J. Rossi, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Panel Discussion: Focal Therapy

John W. Davis, MD, FACS, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

Prostate Cancer in the Veteran Population Roundtable

Peter F. Orio III, DO, MS, moderated this roundtable discussion at the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

SESSION 7: High Risk Localized and Oligometastatic Disease

Challenging the Role of Pelvic Lymph Node Dissection at Robotic Prostatectomy

John W. Davis, MD, FACS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Pelvic Lymph Node Management: Radiation Approach

Jason A. Efstathiou, MD, DPhil, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Staging Updates: Whole Body MRI and PET Imaging for Prostate Cancer

Brian T. Helfand, MD, PhD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

ADT and Radiation

Mira Keyes MD, FRCPC, FABS, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Panel Discussion: High Risk Localized and Oligometastatic Disease

Charles J. Ryan, MD, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

SESSION 8: Advanced Prostate Cancer: Part 1

mHSPC : Latest Approaches and Clinical Trials

Tanya B. Dorf, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

PARP in mCRPC

Daniel P. Petrylak, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

New Concepts in Molecularly Targeted Radiation in Prostate Cancer

Oliver Sartor, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Advanced Prostate Cancer Clinics (APCC): LUGPA Perspective

Ronald P. Kaufman, Jr., MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 11, 2025, in Vail, Colorado.

Panel Discussion: Advanced Prostate Cancer: Part 1

Brian J. Davis, MD, PhD, moderated this panel discussion at the 35th Annual International Prostate Cancer Update on February 10, 2025, in Vail, Colorado.

SESSION 9: Advanced Prostate Cancer: Part 2

ARPi Combinations in mCRPC

Tanya B. Dorf, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

Advanced Prostate Cancer: When and How to Radiate

Jason A. Efstathiou, MD, DPhil, presented this lecture during the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

Future of AR-Directed Therapy

Andrew W. Hahn, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

Ongoing Clinical Trials Update

Daniel P. Petrylak, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

SESSION 10: What’s Next for Prostate Cancer?

A Review of Prostate Cancer Perirectal Spacers

Jonathan D. Tward, MD, PhD, FASTRO, presented this lecture during the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

Prediction of Extraprostatic Disease: Updates on NeuroSAFE, Histologic Scanner, Conventional Nomograms/Imaging, & AI-Assisted Prostate Cancer Mapping

David M. Albala, MD, presented this lecture during the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

Expert Panel: Which Patients Do You Struggle With the Most, and What Makes You Sweat?

John W. Davis, MD, FACS, moderated this expert panel discussion at the 35th Annual International Prostate Cancer Update on February 12, 2025, in Vail, Colorado.

Abstract Videos

PEACE-III: A Randomized, Multicenter, Open-Label Phase III Trial Comparing Enzalutamide Versus A Combination of Radium-223 And Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC)

Murilo de Almeida Luz presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

Real-World Head-to-Head Analysis of Overall Survival in Patients with Metastatic Castration Sensitive Prostate Cancer Initiated on Apalutamide versus Enzalutamide in the United States

Sabree Burbage presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

Predictive Value of IsoPSA and ExoDx Biomarker Tests for Prostate Cancer: A Retrospective Cohort

Alec Martin presented this abstract during the 35th Annual International Prostate Cancer Update in Vail, Colorado.

A Descriptive Analysis of Treatment Patterns and Clinical Outcomes in Patients with metastatic Castration Sensitive Prostate Cancer (mCSPC) who Initiated Apalutamide or Darolutamide in the United States

Sabree Burbage presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

Overall Survival in Patients with metastatic Castration Sensitive Prostate Cancer (mCSPC) Treated with Apalutamide versus Abiraterone Acetate – A Head-to-head Analysis of Real-world Patients in the United States

Sabree Burbage presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

Multidisciplinary Approach to Oligometastatic Prostate Cancer, Preserving Sexual and Urinary Function Without Hormone Therapy

Felipe Balbontin presented this abstract during the 35th Annual International Prostate Cancer Update Conference in Vail, Colorado.

Low Dose Rate Brachytherapy as Monotherapy in Unfavorable Intermediate and High Risk Prostate Cancer in a Single Center

Felipe Balbontin presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

Elective Pelvic Lymph Node Radiation Therapy in Patients with Localized Prostate Cancer: A Post Randomization Analysis

Mutlay Sayan presented this abstract during the 35th Annual International Prostate Cancer Update Conference in Vail, Colorado.

Comparison of Real-world Overall Survival in Subgroups of Patients with metastatic Castration-Sensitive Prostate Cancer treated with Apalutamide or Enzalutamide

Sabree Burbage presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

The Prostatype Genomic Classifier (PGC) Outperforms Clinical Models in Predicting Prostate Cancer-Specific Mortality (PCSM): A Multi-Cohort International Analysis

Gerald Andriole presented this abstract during the 35th Annual International Prostate Cancer Update Conference in Vail, Colorado.

Head-to-head Comparison of Overall Survival in Subgroups of Patients with metastatic Castration-Sensitive Prostate Cancer initiating Apalutamide or Abiraterone acetate – A Real-World Study

Sabree Burbage presented this abstract during the 35th Annual International Prostate Cancer Conference in Vail, Colorado.

The Impact of the SMARTBX™ System on Prostate Cancer Detection

Christopher Keel presented this abstract during the 35th Annual International Prostate Cancer Update Conference in Vail, Colorado.